Os níveis séricos de Cyfra 21-1 são factores preditivos da sobrevida dos doentes com carcinoma pulmonar de não pequenas células submetidos a gefitinib como terapêutica de terceira linha.

Barlési, F.; Tchouhadjian, C.; Doddoli, C.; Torre, J.-P.; Astoul, P.; Kleisbauer, J.-P.

doi:10.1016/S0873-2159(15)30508-0

Article information

Download PDF

Statistics

Full text is only aviable in PDF

Bibliografia

[1.]

N. Reinmuth, B. Brandt, M. Semik, W.P. Kunze, R. Achatzy, H.H. Sheld, P. Broermann, W.E. Berdel, H.N. Macha, M. Thomas.

Prognostic impact of Cyfra 21-1 and other serum markers in completed resected non-small cell lung cancer.

Lung Cancer, 36 (2002), pp. 265-270

Medline

[2.]

D.G. Pfister, D.H. Johnson, C.G. Azzoli, W. Sause, T.J. Smith, S. Baker Jr., J. Olak, D. Stover, J.R. Strawn, A.T. Turrisi, M.R. Somerfield.

American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline update 2003.

J Clin Oncol, 22 (2004), pp. 330-353

http://dx.doi.org/10.1200/JCO.2004.09.053 | Medline

[3.]

T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman, D.A. Haber.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

N Engl J Med, 350 (2004), pp. 2129-2139

http://dx.doi.org/10.1056/NEJMoa040938 | Medline

[4.]

J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, M. Meyerson.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Science, 304 (2004), pp. 1497-1500

http://dx.doi.org/10.1126/science.1099314 | Medline

[5.]

S.-W. Han, T.-Y. Kim, P.G. Hwang, S. Jeong, J. Kim, I.S. Choi, D.-Y. Oh, J.H. Kim, D.H. Chung, S.-H. Im, Y.T. Kim, J.S. Lee, D.S. Heo, Y.-J. Bang, N.K. Kim.

Predictive and prognostic impact o epidermal growth factor mutation in non-small-cell lung cancer patients treated with gefitinib.

J Clin Oncol, 23 (2005), pp. 2493-2501

http://dx.doi.org/10.1200/JCO.2005.01.388 | Medline

[6.]

W. Pao, V.A. Miller.

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

J Clin Oncol, 23 (2005), pp. 2556-2568

http://dx.doi.org/10.1200/JCO.2005.07.799 | Medline

[7.]

J.L. Pujol, O. Molinier, W. Ebert, J.P. Daures, F. Barlesi, G. Buccheri, M. Paesmans, E. Quoix, D. Moro-Sibilot, M. Szturmowicz, J.M. Brechot, T. Muley, J. Grenier.

Cyfra 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients.

Br J Cancer, 90 (2004), pp. 2097-2105

http://dx.doi.org/10.1038/sj.bjc.6601851 | Medline

[8.]

F. Barlési, C. Gimenez, J.P. Torre, C. Doddoli, J. Mancini, L. Greillier, F. Roux, J.P. Kleisbauer.

Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer.

Respir Med, 98 (2004), pp. 357-362

Medline

[9.]

G. Buccheri, D. Ferrigno.

Prognostic factors.

Hematol Oncol Clin N Am, 18 (2004), pp. 187-201

[10.]

N.T. Shah, M.G. Kris, W. Pao, L.B. Tyson, B.M. Pizzo, M.-H. Heinemann, L. Ben-Porat, D.L. Sachs, T.R. Heelan, V.A. Miller.

Practical management of patients with non-small-cell lung cancer treated with gefitinib.

J Clin Oncol, 23 (2005), pp. 165-174

http://dx.doi.org/10.1200/JCO.2005.04.057 | Medline

[11.]

T. Berghmans, A.P. Meert, B. Martin, V. Ninane, J.-P. Sculier.

Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer.

Eur Respir J, 25 (2005), pp. 329-335

http://dx.doi.org/10.1183/09031936.05.00060804 | Medline

[12.]

V.A. Miller, M.G. Kris, N. Shah, J. Patel, C. Azzoli, J. Gomez, L.M. Krug, W. Pao, N. Rizvi, B. Pizzo, L. Tyson, E. Venkatraman, L. Ben-Porat, N. Memoli, M. Zakowski, V. Rusch, R.T. Heelan.

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

J Clin Oncol, 22 (2004), pp. 1103-1109

http://dx.doi.org/10.1200/JCO.2004.08.158 | Medline

[13.]

N. van Zandwijk.

Tolerability of gefitinib in patients receiving treatment in everyday clinical practice.

Br J Cancer, 89 (2003), pp. S9-S14

http://dx.doi.org/10.1038/sj.bjc.6601477 | Medline

Indexed in:

Follow us:

Indexed in:

Follow us:

Subscribe to our newsletter